Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort - Grosicki, Sebastian; Mellqvist, Ulf-Henrik; Pruchniewski, Lukasz; Crafoord, Jacob; Trudel, Suzanne; Min, Chang-Ki; White, Darrell; Alegre, Adrian; Hansson, Markus; Ikeda, Takashi; Sunami, Kazutaka; Leip, Eric; et al. (Blood, 2022)